Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierAdaptive Biotechnologies Corporation (“we,” “us” or “our”) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $71.6MThe company’s own SEC segment disclosure.
- Service$66.2M92%
- Service And Licensing$5.4M8%
Adaptive Biotechnologies Corporation (ADPT) reported revenue of $72M in Q2 2026 (quarter ended Jun 30, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 72% and net loss of $40M. For the full year FY2025, revenue was $277M (+55% year on year) and net income −$59M. Its largest product in Q2 2026 was Service at $66M, 92% of the disclosed total, well ahead of Service And Licensing at 7.5%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #5 of 17 by Smart Score